+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.

Age: 18Years +All GendersPhase 3
318 locations
D

Actively Recruiting

Researchers are evaluating if patients with acute heart failure can achieve the same level of heart failure medication management through digital follow-up at home compared to traditional hospital visits, based on the STRONG-HF strategy. This study addresses the challenge of low use of recommended heart failure therapies despite evidence showing they reduce mortality, aiming to improve care delivery by testing remote medication up-titration and follow-up. The trial builds on the STRONG-HF trials success, which showed better outcomes with early medication adjustment and follow-up in specialized clinics but faced barriers due to frequent hospital visits. Participants will be randomly assigned to one of two groups one receiving follow-up and heart failure medication management at home via telecommunication led by specialized nurses, including home visits at 1, 2, 3, and 6 weeks plus a primary care physician visit around week 2 the other group receiving follow-up and medication management at hospital outpatient clinics on the same schedule. Both groups follow the STRONG-HF intensive care strategy with early and rapid medication up-titration to at least half the maximum tolerated doses at discharge and then to maximum tolerated doses after 2 weeks, with safety visits at weeks 1, 3, and 6. During the 90-day study period, participants will be monitored for medication doses, heart function via echocardiography, blood tests including NT-proBNP, quality of life assessments, self-care, and patient satisfaction. Readmissions and survival will be tracked for up to 24 months. Follow-up visits occur weekly during the first 6 weeks, and researchers will assess treatment adherence, adverse events, and healthcare costs. This approach aims to reduce the burden on patients and healthcare systems while maintaining effective heart failure care.

Age: 18Years +All GendersPhase Not Applicable
11 locations
C

Actively Recruiting

Osteoarthritis of the joint between the forearm bones at the wrist, called the distal radioulnar joint DRUJ, can cause pain and reduce the ability to lift and rotate the forearm. This condition often develops after fractures, ligament injuries, or degenerative wrist disease. Researchers are comparing two surgical treatmentsthe Darrach procedure, which removes the ulnar head, and ulnar head replacement with a prosthetic implantto determine which method provides better function and fewer complications in patients with stable but painful DRUJ osteoarthritis. The study involves two groups one undergoing the Darrach procedure and the other receiving a ulnar head replacement using the Herbert Ulnar Head Prosthesis. The surgeries are performed at several hand surgery centers in Norway, following standardized methods. Both groups receive the same postoperative care and follow-up schedule. Participants are randomly assigned to one of the two surgical options to fairly compare outcomes. Participants will be assessed before surgery and then followed up at 3 months, 1 year, and 5 years after the procedure. Evaluations include range of motion, grip strength, functional scores such as the Norwegian version of Quick DASH, patient-related wrist and hand evaluations, pain scales, and monitoring for any complications or additional surgeries. The study aims to gather detailed long-term data on how each surgery affects wrist function and pain over five years.

Age: 30Years - 75YearsAll GendersPhase Not Applicable
6 locations
S

Actively Recruiting

This research aims to identify factors that predict the clinical course and treatment response in patients undergoing Dialectical Behaviour Therapy DBT for self-harm and borderline personality disorder in Norway. The study collects uniform and systematic clinical data from patients treated in various clinical units offering DBT, focusing on patient characteristics, treatment effects, and outcomes over time. Participants receive DBT adapted to their age group, with adolescents undergoing a 20-week program including weekly individual therapy, multi-family skills training, family therapy as needed, and telephone coaching. Adults receive a standard DBT program lasting 52 weeks, featuring weekly individual therapy, skills training, and telephone coaching. Assessments occur before treatment, at intervals during treatment, at treatment end, and at follow-up. During the study, participants complete interviews and rating scales administered by clinicians, as well as electronic self-reports on tablets and through a mobile app capturing emotions and behaviors multiple times daily. Researchers measure outcomes such as self-harm behavior, suicidal ideation, depressive symptoms, borderline symptoms, and hopelessness at various time points. The study is conducted over several years, with continuous data collection and monitoring.

Age: 12Years - 70YearsAll GendersPhase Not Applicable
5 locations